Dissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications.
Movat's pentachrome stain
Picrosirius
immunohistochemistry
malignant mesothelioma
prognosis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
02
2022
accepted:
16
03
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Malignant pleural mesotheliomas (MM) are known for their heterogenous histology and clinical behavior. MM histology reveals three major tumor cell populations: epithelioid, sarcomatoid, and biphasic. Using a dissecting approach, we showed that histochemical gradients help us better understand tumor heterogeneity and reconsider its histologic classifications. We also showed that this method to characterize MM tumor cell populations provides a better understanding of the underlying mechanisms for invasion and disease progression. In a cohort of 87 patients with surgically excised MM, we used hematoxylin and eosin to characterize tumor cell populations and Movat's pentachrome staining to dissect the ECM matrisome. Next, we developed a computerized semi-assisted protocol to quantify and reconstruct the ECM in 3D and examined the clinical association between the matricellular factors and patient outcome. Epithelioid cells had a higher matrix composition of elastin and fibrin, whereas, in the sarcomatoid type, hyaluronic acid and total collagen were most prevalent. The 3D reconstruction exposed the collagen I and III that form channels surrounding the neoplastic cell blocks. The estimated volume of the two collagen fractions was 14% of the total volume, consistent with the median estimated area of total collagen (12.05 mm Differential patterns in matricellular phenotypes in MM could be used in translational studies to improve patient outcome. More importantly, our data raise the possibility that cancer cells can use the matrisome for disease expansion and could be effectively targeted by anti-collagen, anti-elastin, and/or anti-hyaluronic acid therapies.
Sections du résumé
Background
UNASSIGNED
Malignant pleural mesotheliomas (MM) are known for their heterogenous histology and clinical behavior. MM histology reveals three major tumor cell populations: epithelioid, sarcomatoid, and biphasic. Using a dissecting approach, we showed that histochemical gradients help us better understand tumor heterogeneity and reconsider its histologic classifications. We also showed that this method to characterize MM tumor cell populations provides a better understanding of the underlying mechanisms for invasion and disease progression.
Methods
UNASSIGNED
In a cohort of 87 patients with surgically excised MM, we used hematoxylin and eosin to characterize tumor cell populations and Movat's pentachrome staining to dissect the ECM matrisome. Next, we developed a computerized semi-assisted protocol to quantify and reconstruct the ECM in 3D and examined the clinical association between the matricellular factors and patient outcome.
Results
UNASSIGNED
Epithelioid cells had a higher matrix composition of elastin and fibrin, whereas, in the sarcomatoid type, hyaluronic acid and total collagen were most prevalent. The 3D reconstruction exposed the collagen I and III that form channels surrounding the neoplastic cell blocks. The estimated volume of the two collagen fractions was 14% of the total volume, consistent with the median estimated area of total collagen (12.05 mm
Conclusion
UNASSIGNED
Differential patterns in matricellular phenotypes in MM could be used in translational studies to improve patient outcome. More importantly, our data raise the possibility that cancer cells can use the matrisome for disease expansion and could be effectively targeted by anti-collagen, anti-elastin, and/or anti-hyaluronic acid therapies.
Identifiants
pubmed: 35492318
doi: 10.3389/fmed.2022.871202
pmc: PMC9043486
doi:
Types de publication
Journal Article
Langues
eng
Pagination
871202Informations de copyright
Copyright © 2022 Balancin, Baldavira, Prieto, Machado-Rugolo, Farhat, Assato, Velosa, Teodoro, Ab'Saber, Takagaki and Capelozzi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Br J Cancer. 2010 Nov 9;103(10):1562-70
pubmed: 20959825
Arch Pathol Lab Med. 2018 May;142(5):645-661
pubmed: 29480761
Nat Med. 2011 Mar;17(3):320-9
pubmed: 21383745
J Microsc. 2010 Nov;240(2):122-9
pubmed: 20946378
Science. 2005 Nov 18;310(5751):1139-43
pubmed: 16293750
Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1053-8
pubmed: 25550505
Clin Exp Pharmacol Physiol. 2021 Apr;48(4):543-552
pubmed: 33336399
JCI Insight. 2016 Apr 21;1(5):
pubmed: 27275013
Front Pharmacol. 2016 Mar 04;7:32
pubmed: 26973522
Wound Repair Regen. 2009 Mar-Apr;17(2):153-62
pubmed: 19320882
Glycobiology. 2002 Mar;12(3):37R-42R
pubmed: 11971857
Cancer Res. 1998 Jan 15;58(2):342-7
pubmed: 9443415
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Arch Pathol Lab Med. 2018 Jan;142(1):89-108
pubmed: 28686500
J Thorac Dis. 2015 Jun;7(6):964-80
pubmed: 26150910
Nat Rev Cancer. 2017 Jul 25;17(8):475-488
pubmed: 28740119
Hum Pathol. 2021 Jan;107:58-68
pubmed: 33161029
Histochemistry. 1980 Feb;65(2):131-41
pubmed: 6153646
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Br J Cancer. 2014 Jul 8;111(1):139-48
pubmed: 24874477
Acta Biomater. 2015 Feb;13:61-7
pubmed: 25462839
Pathology. 2011 Feb;43(2):128-32
pubmed: 21233673
Br J Cancer. 2017 Oct 24;117(9):1341-1348
pubmed: 28817839
Histopathology. 2018 Aug;73(2):327-338
pubmed: 29575153
Nat Commun. 2018 Oct 8;9(1):4144
pubmed: 30297715
Adv Wound Care (New Rochelle). 2016 Mar 1;5(3):119-136
pubmed: 26989578
J Oral Maxillofac Pathol. 2016 Sep-Dec;20(3):405-412
pubmed: 27721605
N Engl J Med. 1999 Sep 2;341(10):738-46
pubmed: 10471461
Adv Drug Deliv Rev. 2007 Nov 10;59(13):1351-65
pubmed: 17804111
Ann Ist Super Sanita. 2015;51(1):52-9
pubmed: 25857384
Matrix Biol. 2017 Jul;60-61:38-56
pubmed: 27932299
Nat Commun. 2019 Mar 22;10(1):1333
pubmed: 30902996
PLoS One. 2012;7(6):e38011
pubmed: 22723842
Int J Cancer. 2008 May 1;122(9):1972-80
pubmed: 18076073
Ann Clin Lab Sci. 1973 May-Jun;3(3):207-11
pubmed: 4122202
Am J Pathol. 1991 Mar;138(3):629-46
pubmed: 2000940
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Eur J Vasc Endovasc Surg. 2002 Nov;24(5):440-4
pubmed: 12435345
Glia. 1999 Jan 15;25(2):179-89
pubmed: 9890632
Cancer Res. 2013 Jul 1;73(13):3833-41
pubmed: 23633490
J Histochem Cytochem. 2014 Oct;62(10):751-8
pubmed: 25023614
APL Bioeng. 2020 May 05;4(2):026105
pubmed: 32455252
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Br J Ophthalmol. 2014 Feb;98(2):159-61
pubmed: 24288392
IEEE Comput Graph Appl. 2013 Nov-Dec;33(6):26-34
pubmed: 24808128
Cancer Metastasis Rev. 2014 Dec;33(4):1059-79
pubmed: 25324146
Curr Opin Biotechnol. 2003 Oct;14(5):538-46
pubmed: 14580586
Cancer Cell. 2005 Sep;8(3):241-54
pubmed: 16169468
J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42
pubmed: 15838603
Matrix Biol. 2016 Jan;49:10-24
pubmed: 26163349
J Thorac Oncol. 2017 May;12(5):850-859
pubmed: 28257959
Exp Cell Res. 1995 Oct;220(2):312-24
pubmed: 7556439
Cancer Res. 2000 Jan 1;60(1):150-5
pubmed: 10646867
Front Oncol. 2017 Oct 09;7:242
pubmed: 29062810
Arch Pathol. 1972 Aug;94(2):187-91
pubmed: 4114784
Oman Med J. 2021 Mar 31;36(2):e247
pubmed: 33898059
Mod Pathol. 2012 Feb;25(2):260-71
pubmed: 21983936
AMA Arch Pathol. 1955 Sep;60(3):289-95
pubmed: 13248341
Histochem J. 1979 Jul;11(4):447-55
pubmed: 91593
Biomaterials. 2008 Jul;29(20):2969-76
pubmed: 18433861
Bioinformatics. 2017 Aug 01;33(15):2424-2426
pubmed: 28369169